777 replies to this topic

[ImmInst]

BIOTIME, INC. : CORRECTING AND REPLACING BioTime Announces Fourth Quarter and ...
4-traders - 5 hours ago

BioTime, Inc. : CORRECTING AND REPLACING BioTime Announces Fourth Quarter and Fiscal Year End 2011 Financial Results and Recent Corporate Accomplishments Please replace the release with the following corrected version due to revisions to footnote 2 of ...

View the full article

[ImmInst]

CORRECTING AND REPLACING BioTime Announces Fourth Quarter and Fiscal Year End ...
MarketWatch (press release) - 5 hours ago

ALAMEDA, Calif., Mar 14, 2012 (BUSINESS WIRE) -- Please replace the release with the following corrected version due to revisions to footnote 2 of the Condensed Consolidated Statement of Operations.

View the full article

[ImmInst]

BioTime Announces Fourth Quarter And Fiscal Year End 2011 Financial Results ...
TheStreet.com (press release) - 11 hours ago

By Business Wire 03/14/12 - 04:23 PM EDT Please replace the release with the following corrected version due to revisions to footnote 2 of the Condensed Consolidated Statement of Operations.

View the full article

[ImmInst]

FDA Approves First Generic To Treat Depression; Endocyte to Submit EU ...
Proactive Investors USA & Canada - Mar 15, 2012

Below is a look at some of the headlines for companies that made news in the healthcare sector on March 14, 2012. Teva Pharmaceutical Industries (NASDAQ:TEVA) / IVAX Pharmaceuticals (NYSE:IVD) gained FDA approved the first generic Lexapro (escitalopram ...

View the full article

[ImmInst]

BioTime Q4 Loss Widens
NASDAQ - Mar 14, 2012

(RTTNews.com) - BioTime Inc. (BTX) Wednesday reported fourth-quarter net loss attributable to the company of $5.1 million or $0.10 per share, compared to $3.0 million or $0.06 per share in the same period last year.

View the full article

[ImmInst]

BioTime CEO Michael D. West To Present At 2012 Maxim Group Growth Conference
TheStreet.com (press release) - 4 hours ago

By Business Wire 03/21/12 - 04:14 PM EDT BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West, Ph.

View the full article

[ImmInst]

BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the ...
PharmiWeb.com (press release) - 4 hours ago

BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary OncoCyte Corporation today provided a progress report on the development of PanC-DxTM, a novel diagnostic device developed at BioTime and OncoCyte to detect the presence of various human cancers ...

View the full article

[ImmInst]

BIOTIME, INC. : BioTime's Subsidiary OncoCyte Corporation Provides an Update ...
4-traders - 8 hours ago

BioTime, Inc. : BioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM ALAMEDA, Calif.

View the full article

[ImmInst]

Mesoblast Update to Credit Suisse Asia Investment Conference
irasia.com (press release) - 3 hours ago

Melbourne, Australia; Monday 26 March 2012: Global regenerative medicine company, Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), has provided investors with an update on the company's clinical programs at the Credit Suisse 15 th Asia Investment ...

View the full article

[ImmInst]

BioTime Releases Progress Report On Development Of Pan-Cancer Product PanC-Dx
RTT News - Mar 22, 2012

(RTTNews) - Biotechnology company BioTime Inc (BTX: News ) Thursday provided a progress report on PanC-Dx, a novel diagnostic device developed to detect the presence of various human cancers, in association with its subsidiary unit, ...

BioTime's Subsidiary OncoCyte Corporation Provides an Update on the ... - MarketWatch (press release)
BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference - EON: Enhanced Online News (press release)

View the full article

[ImmInst]

BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
MarketWatch (press release) - Mar 21, 2012

ALAMEDA, Calif., Mar 21, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) , a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D. West, Ph.

View the full article

[ImmInst]

BioTime Is Running Out Of Time - Short-Sell Idea
Seeking Alpha - 28 minutes ago

My hedge fund is short Biotime (BTX), a speculative "regenerative medicine" company. Biotime trades for a value of $221 million, but I think the company's enterprise is worth something closer to $20 million.

View the full article

[ImmInst]

BioTime Board Of Directors Forms Science And Technology Committee
TheStreet.com (press release) - 23 hours ago

By Business Wire 04/12/12 - 08:45 AM EDT BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime's technology and ...

View the full article

[ImmInst]

BIOTIME, INC. : BioTime CEO Michael D. West to Present at the 8th GTC Stem ...
4-traders - 40 minutes ago

BioTime, Inc. : BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012 BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief ...

BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012 - MarketWatch (press release)

View the full article

[ImmInst]

BioTime CEO Michael D. West To Present At The 8th GTC Stem Cell Summit 2012
TheStreet.com (press release) - 18 hours ago

By Business Wire 04/16/12 - 08:45 AM EDT BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.

View the full article

[ImmInst]

MESOBLAST LIMITED : 17 April 2012 - Intervertebral Disc Repair Phase 2 Trial ...
4-traders - 1 hour ago

Intervertebral Disc Repair Phase 2 Trial Update Rapid Patient Accrual, Enrolment Reaches Half Way Mark Positive Preclinical Study Results Published in Premier Neurosurgical Journal Melbourne, Australia; 17 April 2012: Global regenerative medicine ...

View the full article

[ImmInst]

Intervertebral Disc Repair Phase 2 Trial Update
MarketWatch (press release) - 32 minutes ago

MELBOURNE, Australia, April 17, 2012 /PRNewswire via COMTEX/ -- Global regenerative medicine company Mesoblast Limited (asx:MSB) today announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, ...

View the full article

[ImmInst]

Mesoblast hits 50% enrolment for back pain trial
Australian Life Scientist - 8 hours ago

Mesoblast (ASX:MSB) has enrolled half the patients for a US trial of off the shelf stem cells to restore degenerated intervertebral discs.

View the full article

[ImmInst]

BIOTIME, INC. : BioTime CEO Michael D. West to Present at the Future Leaders ...
4-traders - 1 hour ago

BioTime, Inc. : BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, ...

BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech ... - MarketWatch (press release)

View the full article

[ImmInst]

Intervertebral disc repair phase 2 trial update from Mesoblast
News-Medical.net - 17 hours ago

Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated ...

Intervertebral Disc Repair Phase 2 Trial Update - MarketWatch (press release)

View the full article

[ImmInst]

BioTime: A Track Record Of Broken Promises
Seeking Alpha - 19 hours ago

Our extensive research has led us to conclude that BioTime (BTX) is grossly overvalued and that its shares should trade at a small premium to the company's cash balance - currently 45 cents per share.

View the full article

[ImmInst]

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
MarketWatch (press release) - 2 hours ago

ALAMEDA, Calif. & CAMBRIDGE, Mass., Apr 20, 2012 (BUSINESS WIRE) -- --LifeMap Sciences will use new family of online databases to promote the sale of stem cell research products and for discovery of regenerative medicine therapeutic products, ...

BioTime Unit LifeMap Sciences To Buy Privately Held XenneX - Quick Facts - NASDAQ

View the full article

[ImmInst]

BioTime Unit LifeMap Sciences To Buy Privately Held XenneX - Quick Facts
NASDAQ - 18 hours ago

(RTTNews.com) - Biotechnology company BioTime, Inc. (BTX) on Friday said it have signed a definitive agreement, under which its wholly owned subsidiary LifeMap Sciences will acquire privately held company XenneX, Inc. The acquisition is expected to ...

View the full article

[ImmInst]

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
SunHerald.com - 23 hours ago

ALAMEDA, Calif. & CAMBRIDGE, Mass. -- BioTime, Inc. (NYSE Amex:BTX) and its wholly owned subsidiary LifeMap Sciences today announced that they have signed a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences.

View the full article

[ImmInst]

BioTime Demonstrates Efficient Method for the Manufacture of Cartilage ...
MarketWatch (press release) - 20 minutes ago

ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a ...

View the full article

[ImmInst]

BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical ...
MarketWatch (press release) - 5 hours ago

ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime's subsidiary ReCyte Therapeutics, Inc. will provide and update on the development of ...

View the full article

[ImmInst]

BioTime's Subsidiary OncoCyte Corporation Provides Update On PanC-DxTM, And ...
TheStreet.com (press release) - 5 hours ago

By Business Wire 04/23/12 - 02:23 PM EDT BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.

View the full article

[ImmInst]

BIOTIME, INC. : BioTime Provides Update on ReneviaTM Product Development
4-traders - 5 hours ago

BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia TM (formerly known as HyStem®-Rx) at an investor meeting in New York City.

View the full article

[ImmInst]

BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen ...
MarketWatch (press release) - 5 hours ago

ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) announced today that Charles S. Irving, Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd.

View the full article

[ImmInst]

BioTime Demonstrates Efficient Method for the Manufacture of Cartilage ...
SunHerald.com - 10 hours ago

ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the ...

View the full article